

REMARKS

Claims 44-95 have been added, and claims 1-43 have been canceled, without prejudice to or disclaimer of the subject matter encompassed by the original claims. New claims 44-66 recite methods for treating a symptom of a lower urinary tract disorder, more particularly methods of using the $\alpha_2\delta$ subunit calcium channel modulators Gabapentin and Pregabalin, and the antimuscarinics Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride to treat a symptom of a lower urinary tract disorder. Support for the recitation of these methods resides in original claims 1-28, and throughout the specification, for example, from page 30 line 17 to page 31 line 25, and page 41 line 16 to page 42 line 17. New claims 67-89 recite pharmaceutical compositions encompassing the $\alpha_2\delta$ subunit calcium channel modulators Gabapentin and Pregabalin and the antimuscarinics Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride. Support for the recitation of these pharmaceutical compositions resides in original claims 29-37, and throughout the specification, for example, from page 30 line 17 to page 31 line 25, and page 41 line 16 to page 42 line 17. New claims 90-95 recite packaged kits for treating a symptom of a lower urinary tract disorder. Support for the recitation of these packaged kits resides in original claims 38-43, and throughout the specification, for example, from page 91 line 16 to page 92 line 22. Because no new matter has been added by way of the added claims, the Examiner is respectfully requested to enter these foregoing amendments into the above-referenced application prior to the substantive examination of the application on its merits.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Appl. No.: 10/805,977
Filed: March 22, 2004
Page 12



Respectfully submitted,

Edward R. Ergenzinger, Jr.

Edward R. Ergenzinger, Jr.
Registration No. 47,549

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 9, 2004

Lynda J. Pixley
Lynda-J. Pixley